Immunovant (IMVT)

• Market cap: $3.8B
• 1 day: 0.78%
• 5 days: -2.64%
• 1 month: -1.18%
• 3 months: -11.53%
• 6 months: -5.24%
• Year to date: -37.52%
• 1 year: -28.52%
• 5 years: 61.93%
• 10 years: 159.90%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Employees: 207

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

232% more call options, than puts

Call options by funds: $59.7M | Put options by funds: $18M

40% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]

12% more capital invested

Capital invested by funds: $2.01B [Q2] → $2.25B (+$240M) [Q3]

1.81% more ownership

Funds ownership: 52.09% [Q2] → 53.9% (+1.81%) [Q3]

9% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 65

8% less funds holding

Funds holding: 197 [Q2] → 181 (-16) [Q3]

43% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 37

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $36 39% upside
• Avg. target: $46 79% upside
• High target: $53 105% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Derek Archila 53% 1-year accuracy 19 / 36 met price target	74% upside $45	Overweight Maintained	19 Dec 2024
HC Wainwright & Co. Douglas Tsao 43% 1-year accuracy 72 / 168 met price target	97% upside $51	Buy Reiterated	8 Nov 2024
Raymond James Danielle Brill 64% 1-year accuracy 9 / 14 met price target	39% upside $36	Outperform Reinstated	10 Oct 2024
Oppenheimer Leland Gershell 54% 1-year accuracy 31 / 57 met price target	105% upside $53	Outperform Maintained	9 Oct 2024